valproic acid/debelost

Povezava se shrani v odložišče

Izberite vrsto razvrščanja

Stran 1 iz 88 rezultatov

Clearance of phenytoin and valproic acid is affected by a small body weight reduction in an epileptic obese patient: a case study.

Samo registrirani uporabniki lahko prevajajo članke

Prijava / prijava

The interaction between clearance of phenytoin, valproic acid, phenobarbital and carbamazepine, and changes in body weight was determined in a 19-year-old obese woman with epilepsy (body weight 93 kg, BMI 36.3 kg/m2). The patient, who was given daily oral doses of 100 mg phenobarbital, 350 mg

Steady-state serum concentrations of carbamazepine and valproic acid in obese and lean patients with epilepsy.

Samo registrirani uporabniki lahko prevajajo članke

Prijava / prijava

Steady-state serum concentrations of carbamazepine (CBZ) and valproic acid (VPA) were investigated in normal weight (body mass index; BMI 20 to 25), lean (smaller than 20 BMI) and moderately obese subjects (greater than 25 BMI) who received either 400 mg/day of CBZ or 800 mg/day of VPA. The CBZ

Polycystic ovaries, obesity and insulin resistance in women with epilepsy. A comparative study of carbamazepine and valproic acid in 105 women.

Samo registrirani uporabniki lahko prevajajo članke

Prijava / prijava

In order to investigate the possible role of valproic acid therapy in the development of obesity, hyperinsulinism and polycystic ovaries (PCOs), we have studied metabolic parameters and ovarian morphology in epileptic women. A total of 105 women, who were treated for at least 2 years with valproate

[The prevalence of obesity and metabolic syndrome in paediatric patients with epilepsy treated in monotherapy with valproic acid].

Samo registrirani uporabniki lahko prevajajo članke

Prijava / prijava

BACKGROUND Valproic acid (VPA) is a useful antiepileptic drug for controlling different types of epilepsy. It has several side effects and is associated to increased body weight, as well as metabolic and endocrine disorders, including metabolic syndrome. OBJECTIVE To determine the prevalence of

Effects of valproic acid and levetiracetam monotherapy on carotid intima-media and epicardial adipose tissue thickness in non-obese children with epilepsy.

Samo registrirani uporabniki lahko prevajajo članke

Prijava / prijava

The aim of the study was to investigate the risk of subclinical atherosclerosis independent from obesity and high blood lipid levels in pediatric patients with idiopathic epilepsy receiving valproic acid or levetiracetam monotherapy by evaluating carotid intima-media thickness (CIMT)

The metabolic syndrome in overweight epileptic patients treated with valproic acid.

Samo registrirani uporabniki lahko prevajajo članke

Prijava / prijava

OBJECTIVE To evaluate the presence of metabolic syndrome (MS) in children and adolescents treated with valproate (VPA). METHODS One hundred fourteen patients (54 male and 60 female) were studied. These patients were followed from the beginning of therapy for at least 24 months; at the end of

Valproic acid is a novel activator of AMP-activated protein kinase and decreases liver mass, hepatic fat accumulation, and serum glucose in obese mice.

Samo registrirani uporabniki lahko prevajajo članke

Prijava / prijava

Valproic acid (VPA) is a widely prescribed anticonvulsant for the treatment of epilepsy. Here we demonstrate that VPA is a novel activator of AMP-activated protein kinase (AMPK), a key regulator of cellular metabolism, using primary mouse and human hepatocytes. Incubation of primary mouse

Obesity and plasma concentrations of alpha-tocopherol and beta-carotene in epileptic girls treated with valproate.

Samo registrirani uporabniki lahko prevajajo članke

Prijava / prijava

To investigate whether epileptic patients who become obese after valproic acid (VPA) therapy can have a high risk of atherosclerosis related to the oxidation of low-density lipoprotein, we prospectively studied the plasma concentrations of lipid-soluble antioxidant vitamins in a group of 20

Hepatocellular carcinoma and nonalcoholic steatohepatitis developing during long-term administration of valproic acid.

Samo registrirani uporabniki lahko prevajajo članke

Prijava / prijava

We report a case of hepatocellular carcinoma (HCC) arising in nonalcoholic steatohepatitis (NASH). The patient, a 64-year-old man, was incidentally found to have multiple tumors in the liver when admitted for pneumonia. He had been obese, had been receiving a standard dose of valproic acid since

Body mass index and serum lipid changes during treatment with valproic acid in children with epilepsy.

Samo registrirani uporabniki lahko prevajajo članke

Prijava / prijava

BACKGROUND Valproic acid is the drug of choice for a wide variety of epileptic seizures and syndromes because of its broad spectrum of activity and because, in most patients, it is well tolerated. Although weight gain is a well-known adverse effect of valproic acid therapy, only a few studies have

Association of polycystic ovaries with the use of valproic Acid in jordanian epileptic patients.

Samo registrirani uporabniki lahko prevajajo članke

Prijava / prijava

OBJECTIVE To investigate the frequency of occurrence of polycystic ovaries (PCO) in women taking valproic acid (VPA) as monotherapy for epilepsy. METHODS 163 epileptic patients were seen at the outpatient neurology clinic at Princess's Basma Teaching Hospital, Irbid, and Basheer Hospital, Amman,

Nonalcoholic fatty liver disease in adolescents receiving valproic acid.

Samo registrirani uporabniki lahko prevajajo članke

Prijava / prijava

OBJECTIVE The aim of this study was to investigate the association between the metabolic derangements induced by valproic acid (VPA) and ultrasound-diagnosed nonalcoholic fatty liver disease (NAFLD) in adolescents. METHODS Using a cross-sectional design, we evaluated 86 adolescents with epilepsy who

Ghrelin levels are reduced in prepubertal epileptic children under treatment with carbamazepine or valproic acid.

Samo registrirani uporabniki lahko prevajajo članke

Prijava / prijava

A relationship between ghrelin and epilepsy has been already shown in humans, although the results are controversial. Ghrelin levels are reduced in obesity. Epileptic patients progressively develop a therapy-linked weight gain; however, the mechanisms for this have not been fully explained. The aim

Serum Insulin and Leptin Levels in Children with Epilepsy on Valproate-associated Obesity.

Samo registrirani uporabniki lahko prevajajo članke

Prijava / prijava

BACKGROUND Weight gain is a common adverse effect of sodium valproic acid (VPA) in children with epilepsy. Several mechanisms of VPA-induced obesity have been suggested such as increased appetite, facultative thermogenesis, and elevated insulin and leptin levels. In this study, we aimed to

Treatment of affective disorder and obesity with topiramate.

Samo registrirani uporabniki lahko prevajajo članke

Prijava / prijava

OBJECTIVE To report a case of weight loss and mood stabilization in a patient being treated with the antiepileptic drug topiramate. METHODS A 37-year-old obese white woman with affective instability and obesity was being treated with adjunctive topiramate therapy. The patient lost 10 kg over 10

Prejšnji
1
2
3
4
5
6
Naslednji

Pridružite se naši
facebook strani

Herbal & Natural Medicine

Najbolj popolna baza zdravilnih zelišč, podprta z znanostjo

Deluje v 55 jezikih
Zeliščna zdravila, podprta z znanostjo
Prepoznavanje zelišč po sliki
Interaktivni GPS zemljevid - označite zelišča na lokaciji (kmalu)
Preberite znanstvene publikacije, povezane z vašim iskanjem
Iščite zdravilna zelišča po njihovih učinkih
Organizirajte svoje interese in bodite na tekočem z raziskavami novic, kliničnimi preskušanji in patenti

Vnesite simptom ali bolezen in preberite o zeliščih, ki bi lahko pomagala, vnesite zelišče in si oglejte bolezni in simptome, proti katerim se uporablja.
* Vse informacije temeljijo na objavljenih znanstvenih raziskavah